Fedratinib and Kaletra

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. The risk of adverse reactions such as anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations may increase. Coadministration of a single oral dose of fedratinib (300 mg) with ketoconazole, a potent CYP450 3A4 inhibitor (200 mg twice daily), increased fedratinib total systemic exposure (AUC(inf)) by 3-fold. Simulation and modeling also suggest that ketoconazole (400 mg once daily) may increase the steady state AUC of fedratinib (400 mg once daily) by 2-fold. MANAGEMENT: Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided. However, if coadministration with a potent CYP450 3A4 inhibitor is necessary, the manufacturer recommends that the dose of fedratinib be reduced to 200 mg once daily. Patients should be advised to notify their health care professional if signs and symptoms of anemia, thrombocytopenia, or gastrointestinal, hepatic, or pancreatic toxicity develop. Further dosage adjustment may be required based on patient tolerance and response. When/if concomitant therapy with a potent CYP450 3A4 inhibitor is ceased, the dose of fedratinib should first be increased to 300 mg once daily for two weeks an then increased to 400 mg once daily thereafter as tolerated. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.

ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. The risk of adverse reactions such as anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations may increase. Coadministration of a single oral dose of fedratinib (300 mg) with ketoconazole, a potent CYP450 3A4 inhibitor (200 mg twice daily), increased fedratinib total systemic exposure (AUC(inf)) by 3-fold. Simulation and modeling also suggest that ketoconazole (400 mg once daily) may increase the steady state AUC of fedratinib (400 mg once daily) by 2-fold.

MANAGEMENT: Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided. However, if coadministration with a potent CYP450 3A4 inhibitor is necessary, the manufacturer recommends that the dose of fedratinib be reduced to 200 mg once daily. Patients should be advised to notify their health care professional if signs and symptoms of anemia, thrombocytopenia, or gastrointestinal, hepatic, or pancreatic toxicity develop. Further dosage adjustment may be required based on patient tolerance and response. When/if concomitant therapy with a potent CYP450 3A4 inhibitor is ceased, the dose of fedratinib should first be increased to 300 mg once daily for two weeks an then increased to 400 mg once daily thereafter as tolerated.

Fedratinib

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Fedratinib?

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?